Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 150

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction

Gupta, Manish, Kovar, Andreas, Meibohm, Bernd·2005·The Journal of Clinical Pharmacology
DOI 10.1177/0091270005276847
Open this paper in CoChat — free account

Abstract

Differences in the clinical pharmacology of the 3 currently available oral phosphodiesterase‐5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, are largely determined by their clinical pharmacokinetics as well as their PDE inhibitory activity profile. This review comparatively discusses the major characteristics of the pharmacokinetic profile of all 3 PDE5 inhibitors, including bioavailability and rate of absorption, Biopharmaceutical Classification System categorization, elimination mechanisms, and metabolic profile including active metabolites, as well as the drug‐drug interaction potential and modification of pharmacokinetic properties under selected physiologic and pathophysiologic conditions. The review is aimed at providing comparative clinical pharmacology data to allow for scientifically rational, evidence‐based prescribing and dosing decisions regarding the clinical use of these medications for the treatment of erectile dysfunction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0091270005276847

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 63

  1. 10.1016/0090-4295(88)90303-2 · DOI
  2. 10.5414/CPP40393 · DOI
  3. 10.1038/nrd893 · DOI · Paper page
  4. 10.1007/s11934-003-0027-x · DOI · Paper page
  5. Rosen RC, 2002, PDE‐5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes, Annu Rev Sex Res, 13, 36, 10.1080/10532528.2002.10559802 · DOI
  6. 10.1016/S0735-1097(98)00656-1 · DOI · Paper page
  7. Boolell M, 1996, Sildenafil: an orally active type 5 cyclic GMP‐specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, Int J Impot Res, 8, 47
  8. Center for Drug Evaluation and Research., 1998, NDA 020895 Viagra (Sildenafil Citrate) Tablets: Clinical Pharmacology/Biopharmaceutics Review
  9. European Medicines Agency., 2000, VIAGRA‐Approval Documents: Scientific Discussion & Summary of Product Characteristics
  10. 10.1080/004982599238687 · DOI
  11. Center for Drug Evaluation and Research., 2000, Guidance Document: Waiver of In‐vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System
  12. 10.1046/j.0306-5251.2001.00032.x · DOI
  13. 10.1046/j.0306-5251.2001.00027.x · DOI
  14. 10.1046/j.06-5251.2001.00028.x · DOI
  15. 10.1016/S0149-2918(98)80103-3 · DOI
  16. Warrington JS, 2000, In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions, Drug Metab Dispos, 28, 392
  17. 10.1046/j.0306-5251.2001.00031.x · DOI
  18. 10.1046/j.1365-2125.2000.00245.x · DOI
  19. 10.1097/00007691-200304000-00016 · DOI
  20. 10.1067/mcp.2002.121236 · DOI
  21. 10.1046/j.0306-5251.2001.00030.x · DOI
  22. Hesse C, 2004, Pharmacokinetic and pharmacodynamic evaluation of the interaction between fluvoxamine and sildenafil, Int J Clin Pharmacol Ther, 42, 613
  23. 10.1016/S0090-4295(01)01306-1 · DOI
  24. 10.1016/S0735-1097(00)00705-1 · DOI
  25. 10.1016/S0002-9149(99)00044-2 · DOI · Paper page
  26. 10.1067/mcp.2002.121829 · DOI
  27. 10.1002/cpt1975184377 · DOI
  28. 10.1046/j.0306-5251.2001.00029.x · DOI
  29. 10.1001/jama.283.14.1825 · DOI
  30. Gresser U, 2002, Erectile dysfunction: comparison of efficacy and side effects of the PDE‐5 inhibitors sildenafil, vardenafil and tadalafil‐review of the literature, Eur J Med Res, 7, 435
  31. 10.1007/s003450000168 · DOI
  32. 10.2165/00002512-200219030-00005 · DOI
  33. Center for Drug Evaluation and Research., 2003, NDA 021400 Levitra (Vardenafil Hydrochloride) Tablets: Clinical Pharmacology/Biopharmaceutics Review
  34. European Medicines Agency., 2003, LEVITRA‐Approval Documents: Scientific Discussion & Summary of Product Characteristics
  35. 10.1159/000049770 · DOI
  36. 10.1016/S0090-4295(03)00359-5 · DOI · Paper page
  37. 10.1177/0091270002250604 · DOI · Paper page
  38. 10.1345/aph.1D019 · DOI
  39. Rohde G, 2001, The pharmacokinetics of vardenafil, a selective PDE5 inhibitor, are minimally affected by coadministration with cimetidine and ranitidine [abstract], Pharmacotherapy, 21, 1254
  40. Rohde G, 2001, The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, are not affected by the antacid Maalox 70 [abstract], Pharmacotherapy, 21, 1254
  41. Bauer R‐J, 2002, The interaction of alcohol with vardenafil, a potent and highly selective phosphodiesterase type 5 inhibitor [abstract], Pharmacotherapy, 22, 418
  42. Klotz T, 2002, Effect of renal impairment on the single‐dose pharmacokinetics of vardenafil 20mg, a selective PDE5 inhibitor, for the treatment of erectile dysfunction [abstract], Pharmacotherapy, 22, 418
  43. 10.1016/S0002-9149(03)00824-5 · DOI
  44. 10.2165/00003495-200363200-00004 · DOI · Paper page
  45. Eardley I, 2002, Tadalafil (Cialis) for men with erectile dysfunction, Int J Clin Pract, 56, 300, 10.1111/j.1742-1241.2002.tb11260.x · DOI
  46. 10.1007/s11934-003-0029-8 · DOI
  47. 10.1023/B:PHAM.0000036922.03519.40 · DOI
  48. Brock GB, 2002, Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses, J Urol, 168, 1332, 10.1016/S0022-5347(05)64442-4 · DOI · Paper page
  49. Troconiz IF, 2003, Tadalafil population pharmacokinetics in patients with erectile dysfunction [abstract], AAPS PharmSci, 5
  50. Center for Drug Evaluation and Research., 2003, NDA 021368 Cialis (Tadalafil) Tablets: Clinical Pharmacology/Biopharmaceutics Review
  51. Brock GB, 2003, Tadalafil: a new agent for erectile dysfunction, Can J Urol, 10, 17
  52. 10.1016/S0002-9149(03)00828-2 · DOI
  53. European Medicines Agency., 2002, CIALIS‐Approval Documents: Scientific Discussion & Summary of Product Characteristics
  54. 10.2174/1389200013338658 · DOI
  55. 10.1016/S0002-9149(03)00074-2 · DOI · Paper page
  56. 10.1124/jpet.103.059311 · DOI
  57. 10.1124/dmd.31.11.1306 · DOI
  58. 10.1038/86882 · DOI
  59. 10.1177/00912700122010023 · DOI
  60. 10.1177/0091270003258170 · DOI
  61. 10.2165/00003088-200241050-00002 · DOI · Paper page
  62. 10.1067/mcp.2002.128388 · DOI
  63. 10.1097/01.ju.0000058369.72348.ba · DOI

Cited by

See all 150

Metadata

Authors
Gupta, M., Kovar, A., & Meibohm, B.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2005-09
Volume
45
Issue
9
Pages
987-1003
ISSN
  • 0091-2700
  • 1552-4604
DOI
10.1177/0091270005276847
Cited by
150
References
1
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2756 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.